722 related articles for article (PubMed ID: 31515453)
21. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
[TBL] [Abstract][Full Text] [Related]
22. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
[TBL] [Abstract][Full Text] [Related]
23. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler JH; Hanks BA; Khasraw M
Clin Cancer Res; 2021 Mar; 27(5):1236-1241. PubMed ID: 33199494
[TBL] [Abstract][Full Text] [Related]
24. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.
Wang S; He Z; Wang X; Li H; Liu XS
Elife; 2019 Nov; 8():. PubMed ID: 31767055
[TBL] [Abstract][Full Text] [Related]
25. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW
Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443
[TBL] [Abstract][Full Text] [Related]
26. Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types.
Asleh K; Ouellette RJ
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398121
[TBL] [Abstract][Full Text] [Related]
27. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
[TBL] [Abstract][Full Text] [Related]
28. Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort.
Li Y; Chen Z; Wu L; Tao W
Ann Transl Med; 2020 Apr; 8(7):446. PubMed ID: 32395490
[TBL] [Abstract][Full Text] [Related]
29. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
[TBL] [Abstract][Full Text] [Related]
30. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
32. Immune cell infiltration-associated signature in colon cancer and its prognostic implications.
Deng D; Luo X; Zhang S; Xu Z
Aging (Albany NY); 2021 Aug; 13(15):19696-19709. PubMed ID: 34349038
[TBL] [Abstract][Full Text] [Related]
33. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
[TBL] [Abstract][Full Text] [Related]
34. Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.
Takamatsu S; Hamanishi J; Brown JB; Yamaguchi K; Yamanoi K; Murakami K; Gotoh O; Mori S; Mandai M; Matsumura N
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35868660
[TBL] [Abstract][Full Text] [Related]
35. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Klempner SJ; Fabrizio D; Bane S; Reinhart M; Peoples T; Ali SM; Sokol ES; Frampton G; Schrock AB; Anhorn R; Reddy P
Oncologist; 2020 Jan; 25(1):e147-e159. PubMed ID: 31578273
[TBL] [Abstract][Full Text] [Related]
36. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer.
Guo JN; Chen D; Deng SH; Huang JR; Song JX; Li XY; Cui BB; Liu YL
Cancer Immunol Immunother; 2022 Jun; 71(6):1313-1330. PubMed ID: 34657172
[TBL] [Abstract][Full Text] [Related]
37. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
38. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
39. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.
Liu Z; Lin G; Yan Z; Li L; Wu X; Shi J; He J; Zhao L; Liang H; Wang W
Front Immunol; 2022; 13():989275. PubMed ID: 36238300
[TBL] [Abstract][Full Text] [Related]
40. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]